相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Asciminib: First Approval
Emma D. Deeks
DRUGS (2022)
Current status of therapeutic drug monitoring for methotrexate, imatinib, paclitaxel in China
Weiyan Zhou et al.
CLINICAL BIOCHEMISTRY (2022)
Expression of cytochrome P450 isozyme transcripts and activities in human livers
Jie Liu et al.
XENOBIOTICA (2021)
Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates
Florian Simon et al.
PHARMACEUTICAL RESEARCH (2021)
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients
Sara Demurtas et al.
PHARMACOGENOMICS JOURNAL (2021)
Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature
Camille Lenoir et al.
FRONTIERS IN PHARMACOLOGY (2021)
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment
Matthias Hoch et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib
Chenxiang Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A-mediated drug hepatotoxicity
Jiali Liu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Expression Patterns of Xenobiotic-Metabolizing Enzymes in Tumor and Adjacent Normal Mucosa Tissues among Patients with Colorectal Cancer: The ColoCare Study
Jolantha Beyerle et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation
Nicole Kugler et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors
Camille Azam et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Correlation of PPM1A Downregulation with CYP3A4 Repression in the Tumor Liver Tissue of Hepatocellular Carcinoma Patients
Patrick C. Flannery et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2020)
Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems
Ali Dehshahri et al.
PHARMACOLOGICAL RESEARCH (2020)
Analysis of CYP450 gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients
Luz Maria Torres Espindola et al.
BIOMARKERS (2020)
Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors
Yun-Ting Zhu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant
Ibtissem Hannachi et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2020)
Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters
Chen-Hsi Hsieh et al.
SCIENTIFIC REPORTS (2020)
Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy
Chalirmporn Atasilp et al.
SCIENTIFIC REPORTS (2020)
The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats
Ruba S. Darweesh et al.
BMC PHARMACOLOGY & TOXICOLOGY (2020)
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Liling Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
Alicja Puszkiel et al.
CLINICAL PHARMACOKINETICS (2019)
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study
Alicja Puszkiel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis
Sudhakar M. Pai et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment
Stefanie D. Krens et al.
LANCET ONCOLOGY (2019)
Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
Maarten van Eijk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation
Radek Indra et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer
Tomoko Ozeki et al.
SCIENTIFIC REPORTS (2019)
Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
Samuel J. Reddick et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation
Jennifer E. Bissada et al.
DRUG METABOLISM AND DISPOSITION (2019)
Irinotecan: 25 years of cancer treatment
Christian Bailly
PHARMACOLOGICAL RESEARCH (2019)
Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
Sander Bins et al.
CLINICAL PHARMACOKINETICS (2019)
Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer
Esther Oyaga-Iriarte et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia-inducible factor 1-mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation
Jesus Valencia-Cervantes et al.
ONCOLOGY REPORTS (2019)
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma
Andrew K. L. Goey et al.
PHARMACOGENOMICS (2019)
Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors
Yu-Ting Chang et al.
BLOOD ADVANCES (2019)
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach
Diansong Zhou et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Severe sunitinib-induced myelosuppression in a patient with a CYP 3A4 polymorphism
Nirav D. Patel et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity
Pau Riera et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib
Gracia M. Amaya et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2018)
Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models
Le Yang et al.
EXPERIMENTAL ANIMALS (2018)
Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia
Maiko Abumiya et al.
MEDICAL ONCOLOGY (2018)
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver
Rohitash Jamwal et al.
MOLECULAR PHARMACEUTICS (2018)
2017 FDA drug approvals The FDA approved 46 new drugs last year, the highest total in more than two decades
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2018)
Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
Janneke M. Brussee et al.
PHARMACEUTICAL RESEARCH (2018)
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients
Sarah Sim et al.
PHARMACOGENOMICS (2018)
Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients
Hedy Maagdenberg et al.
PHARMACOGENOMICS (2018)
Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults
Anne van Rongen et al.
CLINICAL PHARMACOKINETICS (2018)
Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects
Poe-Hirr Hsyu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma
M. H. Diekstra et al.
PHARMACOGENOMICS JOURNAL (2017)
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer
D. L. Hertz et al.
PHARMACOGENOMICS JOURNAL (2017)
Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients
Jing Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel
Marion Paolini et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population
Guo-Xin Hu et al.
PHARMACOGENOMICS (2017)
Influence of renal function on pharmacokinetics of antiepileptic drugs metabolized by CYP3A4 in a patient with renal impairment
Yoshiaki Yamamoto et al.
THERAPEUTIC DRUG MONITORING (2017)
Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients
Katsuya Makihara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
Beatrix Wulkersdorfer et al.
CLINICAL PHARMACOKINETICS (2016)
Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib
Richat Abbas et al.
CLINICAL PHARMACOKINETICS (2016)
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
Neil M. Iyengar et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Shabbir Ahmed et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2016)
Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib
Joanna K. Towles et al.
DRUG METABOLISM AND DISPOSITION (2016)
Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia
Najlaa Maddin et al.
ONCOLOGY AND THERAPY (2016)
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor
Paul A. Dickinson et al.
DRUG METABOLISM AND DISPOSITION (2016)
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations
Yi Ling Teo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Inter-patient variability in docetaxel pharmacokinetics: A review
Annemieke J. M. Nieuweboer et al.
CANCER TREATMENT REVIEWS (2015)
CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Dandan Tian et al.
CURRENT DRUG METABOLISM (2015)
Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy
Maria Apellaniz-Ruiz et al.
CLINICAL CANCER RESEARCH (2015)
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients
C. Narjoz et al.
INVESTIGATIONAL NEW DRUGS (2015)
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study
Carmen Fucile et al.
MEDICAL ONCOLOGY (2015)
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
M. Apellaniz-Ruiz et al.
PHARMACOGENOMICS JOURNAL (2015)
Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites
Steven Lacy et al.
DRUG METABOLISM AND DISPOSITION (2015)
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
Simone M. Goldinger et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men
Ellen Scheers et al.
DRUG METABOLISM AND DISPOSITION (2015)
Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22
Simon D. Baxter et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects
Marta Hamilton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Functional Gene Variants of CYP3A4
A. N. Werk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662
M. H. M. Diekstra et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin
Catherine Dutreix et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Sorafenib Metabolism Is Significantly Altered in the Liver Tumor Tissue of Hepatocellular Carcinoma Patient
Ling Ye et al.
PLOS ONE (2014)
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Koji Taniguchi et al.
SEMINARS IN IMMUNOLOGY (2014)
Pathway-Dependent Inhibition of Paclitaxel Hydroxylation by Kinase Inhibitors and Assessment of Drug-Drug Interaction Potentials
Yedong Wang et al.
DRUG METABOLISM AND DISPOSITION (2014)
Studies on the Role of Metabolic Activation in Tyrosine Kinase Inhibitor-Dependent Hepatotoxicity: Induction of CYP3A4 Enhances the Cytotoxicity of Lapatinib in HepaRG Cells
Klarissa D. Hardy et al.
DRUG METABOLISM AND DISPOSITION (2014)
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients
S. J. Seong et al.
ANNALS OF ONCOLOGY (2013)
The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588
Paul W. Manley et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
Wendy A. Teft et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma
Satoshi Noda et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
Anne-Joy M. de Graan et al.
CLINICAL CANCER RESEARCH (2013)
Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis
Raj Vuppalanchi et al.
PLOS ONE (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Comparison of Endogenous 4β-Hydroxycholesterol with Midazolam as Markers for CYP3A4 Induction by Rifampicin
Linda Bjorkhem-Bergman et al.
DRUG METABOLISM AND DISPOSITION (2013)
Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites
Sussan Ghassabian et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
Yi Ling Teo et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates
A. M. Filppula et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
Nicholas Mitsiades et al.
CANCER RESEARCH (2012)
Cytochrome b5 Increases Cytochrome P450 3A4-Mediated Activation of Anticancer Drug Ellipticine to 13-Hydroxyellipticine Whose Covalent Binding to DNA Is Elevated by Sulfotransferases and N,O-Acetyltransferases
Marie Stiborova et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2012)
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2012)
4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans
Ulf Diczfalusy et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Kristine H. Allin et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2011)
Cytokines, Inflammation and Colon Cancer
L. Klampfer
CURRENT CANCER DRUG TARGETS (2011)
In Vitro Cytochrome P450-Mediated Metabolism of Exemestane
Landry K. Kamdem et al.
DRUG METABOLISM AND DISPOSITION (2011)
Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib
Hideo Takakusa et al.
DRUG METABOLISM AND DISPOSITION (2011)
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma
Charline Gomo et al.
INVESTIGATIONAL NEW DRUGS (2011)
Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants
Chiaki Tanaka et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Genetic epidemiology of induced CYP3A4 activity
Nilufer Rahmioglu et al.
PHARMACOGENETICS AND GENOMICS (2011)
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2011)
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients
Chia-Hui Chen et al.
PHARMACOGENOMICS (2011)
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer
Kenichi Sakurai et al.
SURGERY TODAY (2011)
Macrophages, Inflammation, and Insulin Resistance
Jerrold M. Olefsky et al.
ANNUAL REVIEW OF PHYSIOLOGY (2010)
Phase 1 Pharmacokinetic and Drug-Interaction Study of Dasatinib in Patients With Advanced Solid Tumors
Faye M. Johnson et al.
CANCER (2010)
CYP3A4*16 and CYP3A4*18 Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate Drugs
Keiko Maekawa et al.
DRUG METABOLISM AND DISPOSITION (2010)
Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
Woon Chien Teng et al.
MOLECULAR PHARMACOLOGY (2010)
Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study
Priya P. Gor et al.
BREAST CANCER RESEARCH (2010)
Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects
Yong Zeng et al.
ACTA PHARMACOLOGICA SINICA (2009)
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa
Corine Ekhart et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Microtubule dynamics as a target in oncology
April L. Risinger et al.
CANCER TREATMENT REVIEWS (2009)
Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities
Xiaohai Li et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways
Xiaohai Li et al.
DRUG METABOLISM AND DISPOSITION (2009)
Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
Gillian M. Keating et al.
DRUGS (2009)
Molecular Population Genetics of Human CYP3A Locus: Signatures of Positive Selection and Implications for Evolutionary Environmental Medicine
Xiaoping Chen et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2009)
Cytochrome P450s in the development of target-based anticancer drugs
Kedar Purnapatre et al.
CANCER LETTERS (2008)
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study
Mark R. Albertella et al.
CLINICAL CANCER RESEARCH (2008)
Systematic review of the association between circulating interleukin-6 (IL-6) and cancer
Katriina Heikkila et al.
EUROPEAN JOURNAL OF CANCER (2008)
Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing
Marina Kacevska et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Metabolism pathway of vinorelbine (Navelbine®) in human:: Characterisation of the metabolites by HPLC-MS/MS
J. de Graeve et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes
Michael Zhuo Wang et al.
PROTEOMICS (2008)
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients
Kimie Sai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP (TM)) predicts in vivo metabolic inhibition
Ashok Rakhit et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management - The renal insufficiency and anticancer medications (IRMA) study
Vincent Launay-Vacher et al.
CANCER (2007)
Gene-specific effects of inflammatory Cytokines on cytochrome P4502C, 2B6 and 3A4 mRNA levels in human Hepatocytes
Alison E. Aitken et al.
DRUG METABOLISM AND DISPOSITION (2007)
Genetic polymorphisms of CYP3A4:: CYP3A4*18 allele is found in five healthy Malaysian subjects
A. B. Ruzilawati et al.
CLINICA CHIMICA ACTA (2007)
Differences in CYP3A4*1G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations
Jing Du et al.
CLINICA CHIMICA ACTA (2007)
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity
Dhanashri Kolwankar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Transcriptional regulation and expression of CYP3A4 in hepatocytes
Celia P. Martinez-Jimenez et al.
CURRENT DRUG METABOLISM (2007)
The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions
Abdo Haddad et al.
SUPPORTIVE CARE IN CANCER (2007)
Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-β-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma
Serge H. Boyer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Transcriptional repression of hepatic Cytochrome P450 3A4 gene in the presence of cancer
Kellie A. Charles et al.
CLINICAL CANCER RESEARCH (2006)
Mutual repression between steroid and xenobiotic receptor and NF-κB signaling pathways links xenobiotic metabolism and inflammation
Changcheng Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer
Yukiko Nakajima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
The human intestinal cytochrome P450 pie
MF Paine et al.
DRUG METABOLISM AND DISPOSITION (2006)
Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity
A Westlind-Johnsson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations
M Schirmer et al.
PHARMACOGENETICS AND GENOMICS (2006)
Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures
BJ Komoroski et al.
CLINICAL CANCER RESEARCH (2005)
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer
WP Petros et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population
YF Hu et al.
CLINICA CHIMICA ACTA (2005)
Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes
L Quintieri et al.
CLINICAL CANCER RESEARCH (2005)
Cytochrome P450-dependent metabolism of gefitinib
D McKillop et al.
XENOBIOTICA (2005)
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol
HC Swaisland et al.
CLINICAL PHARMACOKINETICS (2005)
CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
R Schmidt et al.
BRITISH JOURNAL OF CANCER (2004)
Effect of St John's wort on imatinib mesylate pharmacokinetics
RF Frye et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes
A Parkinson et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2004)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
The influence of St. John's Wort on the pharmacokinetics and protein binding of imatinib mesylate
P Smith
PHARMACOTHERAPY (2004)
Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A
TS Bekaii-Saab et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2004)
Expression of CYP3A4 in human breast tumour and non-tumour tissues
N Kapucuoglu et al.
CANCER LETTERS (2003)
Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases
LQ Yang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2003)
Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function
R Orlando et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer:: implications for drug therapy
C Martínez et al.
BRITISH JOURNAL OF CANCER (2002)
Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor
B Goodwin et al.
MOLECULAR PHARMACOLOGY (2002)
Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response
LP Rivory et al.
BRITISH JOURNAL OF CANCER (2002)
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer
AB Spurdle et al.
PHARMACOGENETICS (2002)
Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA
PA Jacobson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Tumour cytochrome P450 and drug activation
LH Patterson et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity
E Garcia-Martin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues
Y Miyoshi et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
JK Lamba et al.
PHARMACOGENETICS (2002)
Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts
N Chalasani et al.
HEPATOLOGY (2001)
Identification and functional characterization of eight CYP3A4 protein variants
R Eiselt et al.
PHARMACOGENETICS (2001)
Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat
RB Ewesuedo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Evaluation of the genetic component of variability in CYP3A4 activity:: a repeated drug administration method
V Özdemir et al.
PHARMACOGENETICS (2000)
Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
ZQ Huang et al.
BIOCHEMICAL PHARMACOLOGY (2000)
分享论文
